Name | Title | Contact Details |
---|
We are a clinical stage development and licensing biotechnology company focused on leveraging our Pfenex Expression Technology™ platform to develop and improve protein therapies for unmet patient needs.
The trillions of microbes that call us home – the human microbiome – perform critical functions that preserve our health including helping develop our immune system, manufacturing nutrients such as vitamins, and harvesting energy from the diet. Alterations of the human microbiome are increasingly recognized as a key factor in autoimmune, metabolic, infectious and many other diseases. For millions of years, humans have co-evolved with this community of microbes, communicating in an ancient language that holds critical clues about how autoimmune and infectious diseases develop. This language is based on a system of signals that our resident microbes use to successfully colonize us, such as byproducts of bacterial metabolism and factors that bacteria use to adapt to human niches. Recent discoveries have shown that most of these signals do not lead to disease, rather, they promote our long-term survival. Vedanta Biosciences is developing an innovative class of therapies that modulate pathways of interaction between the human microbiome and the host immune system. Vedanta Biosciences was co-founded by PureTech and a group of world renowned experts in immunology and microbiology.
EpiVax Oncology is developing precision cancer immunotherapies based on mutanome-directed neo-epitopes, selected using proprietary and validated in silico predictive algorithms. Neo-epitopes are mutated and tumor specific epitopes, recognized as non-self, capable of generating highly potent specific T cell immunogenic responses against tumors, translating in improved clinical outcome. EpiVax Oncology is developing neo-epitope based therapeutic vaccines customized and specifically designed for each cancer patient, based on the genetic profiling (using next generation DNA sequencing) of each patient`s unique tumor and normal genome sequence (the mutanome). EpiVax Oncology`s ultimate purpose is to address major unmet medical needs inadequately addressed by other oncology and immuno-oncology treatments which are either only benefiting a very limited subset of patients, or prone to adverse events, or extremely costly and complex to manufacture. EpiVax Oncology`s ambition is to become a premier cancer precision medicine company, leveraging EpiVax`s world class excellence in computational-immunology, genomics and vaccine design, built over the last 20 years.
febit is a Lexington, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Bayer AG is a Baytown, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.